DPM1
Dolichol-phosphate mannose (Dol-P-Man) serves as a donor of mannosyl residues on the lumenal side of the endoplasmic reticulum (ER). Lack of Dol-P-Man results in defective surface expression of GPI-anchored proteins. Dol-P-Man is synthesized from GDP-mannose and dolichol-phosphate on the cytosolic side of the ER by the enzyme dolichyl-phosphate mannosyltransferase. Human DPM1 lacks a carboxy-terminal transmembrane domain and signal sequence and is regulated by DPM2. Mutations in this gene are associated with congenital disorder of glycosylation type Ie. Alternative splicing results in multiple transcript variants.
Full Name
dolichol-phosphate (beta-D) mannosyltransferase 1
Function
Transfers mannose from GDP-mannose to dolichol monophosphate to form dolichol phosphate mannose (Dol-P-Man) which is the mannosyl donor in pathways leading to N-glycosylation, glycosyl phosphatidylinositol membrane anchoring, and O-mannosylation of proteins; catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex.
Biological Process
Dolichol metabolic process Source: MGI
GDP-mannose metabolic process Source: Ensembl
GPI anchor biosynthetic process Source: UniProtKB
Protein mannosylation Source: HGNC-UCL
Protein O-linked mannosylation Source: HGNC-UCL
GDP-mannose metabolic process Source: Ensembl
GPI anchor biosynthetic process Source: UniProtKB
Protein mannosylation Source: HGNC-UCL
Protein O-linked mannosylation Source: HGNC-UCL
Cellular Location
Endoplasmic reticulum
Involvement in disease
Congenital disorder of glycosylation 1E (CDG1E):
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1E patients have features consistent with a dystroglycanopathy and congenital muscular dystrophy, including O-mannosylation defect, camptodactyly, elevated creatine kinase, motor delay and dystrophic changes on muscel biopsy.
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1E patients have features consistent with a dystroglycanopathy and congenital muscular dystrophy, including O-mannosylation defect, camptodactyly, elevated creatine kinase, motor delay and dystrophic changes on muscel biopsy.
View more
Anti-DPM1 antibodies
+ Filters
Loading...
Target: DPM1
Host: Mouse
Antibody Isotype: IgG1, κ
Specificity: Human, Mouse, Rat
Clone: D1559
Application*: WB, IP, IF, E
Target: DPM1
Host: Mouse
Antibody Isotype: IgG
Specificity: Human
Clone: A-5
Application*: WB, IP, IF, E
More Infomation
Hot products 
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Mouse Anti-ATP5F1A Recombinant Antibody (51) (CBMAB-A4043-YC)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503416) (CBMAB-V208-1402-FY)
-
Mouse Anti-C1QC Recombinant Antibody (CBFYC-0600) (CBMAB-C0654-FY)
-
Mouse Anti-ENPP1 Recombinant Antibody (CBFYE-0159) (CBMAB-E0375-FY)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Mouse Anti-CFL1 Recombinant Antibody (CBFYC-1771) (CBMAB-C1833-FY)
-
Mouse Anti-BCL2L1 Recombinant Antibody (H5) (CBMAB-1025CQ)
-
Mouse Anti-14-3-3 Pan Recombinant Antibody (V2-9272) (CBMAB-1181-LY)
-
Mouse Anti-BMI1 Recombinant Antibody (CBYC-P026) (CBMAB-P0108-YC)
-
Mouse Anti-ABIN2 Recombinant Antibody (V2-179106) (CBMAB-A0349-YC)
-
Rat Anti-FABP3 Recombinant Antibody (CBXF-2299) (CBMAB-F1612-CQ)
-
Mouse Anti-CORO1A Recombinant Antibody (4G10) (V2LY-1206-LY806)
-
Mouse Anti-CCN2 Recombinant Antibody (CBFYC-2383) (CBMAB-C2456-FY)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Rabbit Anti-CCN1 Recombinant Antibody (CBWJC-3580) (CBMAB-C4816WJ)
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry



